Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780167 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 269
- Enrollment target
NCT02780167 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 269 participants.
The verdict
NCT02780167, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 269 participants
- Enrollment target
Study Summary
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.
Interventions
- DRUG Placebo
- DRUG PF-04965842
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780167
The ClinicalTrials.gov registry entry for NCT02780167 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02780167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780167 about?
NCT02780167 is a clinical study titled "Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis". Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstra...
What is the current status of trial NCT02780167?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 269 participants. The study started on 2016-04. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02780167?
The interventions under investigation include: Placebo (DRUG), PF-04965842 (DRUG).
Who is sponsoring clinical trial NCT02780167?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.